Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy

Molecular Pharmaceutics

Volumn 4, Issue 5, 2007, Pages 769-781

  Lee, Helen ^a   Hu, Meiduo ^b,c   Reilly, Raymond M ^a,b,c   Allen, Christine ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Active targeting; Block copolymer micelles; Combination therapy; Drug delivery; Ellipticine; Epidermal growth factor (EGF)

Indexed keywords

COPOLYMER; ELLIPTICINE; EPIDERMAL GROWTH FACTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; BYSTANDER EFFECT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICELLE; NANOTECHNOLOGY; PRIORITY JOURNAL;

APOPTOSIS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; EPIDERMAL GROWTH FACTOR; HUMANS; MICELLES; NANOTECHNOLOGY; POLYMERS;

EID: 35549013192     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp0700559     Document Type: Article

References (62)

1. Sebastian, S.; Settleman, J.; Reshkin, S. J.; Azzariti, A.; Bellizzi, A.; Paradiso, A. The complexity of targeting EGFR signalling in cancer: From expression to turnover. Biochim. Biophys. Acta 2006, 1766 (1), 120-139.
2. Lage, A.; Crombet, T.; Gonzalez, G. Targeting epidermal growth factor receptor signaling: Early results and future trends in oncology. Ann. Med. 2003, 35 (5), 327-336.
3. Robertson, K. W.; Reeves, J. R.; Smith, G.; Keith, W. N.; Ozanne, B. W.; Cooke, T. G.; Stanton, P. D. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res. 1996, 56 (16), 3823-3830.
4. Rampaul, R. S.; Pinder, S. E.; Nicholson, R. I.; Gullick, W. J.; Robertson, J. F.; Ellis, I. O. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv. Anat. Pathol. 2005, 12 (5), 271-273.
5. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr.-Relat. Cancer 2001, 8 (1), 3-9.
6. Harris, A. L.; Nicholson, S.; Sainsbury, J. R. C.; Farndon, J.; Wright, C. Epidermal growth-factor receptors in breast-cancer - Association with early relapse and death, poor response to hormones and interactions with neu. J. Steroid Biochem. Mol. Biol. 1989, 34 (1-6), 123-131.
7. Klijn, J. G. M.; Berns, P. M. J. J.; Schmitz, P. I. M.; Foekens, J. A. The clinical-significance of epidermal growth-factor receptor (Egf-R) in human breast-cancer - A review on 5232 patients. Endocr. Rev. 1992, 13 (1), 3-17.
8. Salomon, D. S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19 (3), 183-232.
9. Sainsbury, J. R.; Malcolm, A. J.; Appleton, D. R.; Farndon, J. R.; Harris, A. L. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J. Clin. Pathol. 1985, 38 (11), 1225-1228.
10. Kamath, S.; Buolamwini, J. K. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med. Res. Rev. 2006, 26 (5), 569-594.
11. Carlsson, J.; Kullberg, E. B.; Capala, J.; Sjoberg, S.; Edwards, K.; Gedda, L. Ligand liposomes and boron neutron capture therapy. J. Neurooncol. 2003, 62 (1-2), 47-59.
12. Wolschek, M. F.; Thallinger, C.; Kursa, M.; Rossler, V.; Allen, M.; Lichtenberger, C.; Kircheis, R.; Lucas, T.; Willheim, M.; Reinisch, W.; Gangl, A.; Wagner, E.; Jansen, B. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology 2002, 36 (5), 1106-1114.
13. Mamot, C.; Drummond, D. C.; Noble, C. O.; Kallab, V.; Guo, Z.; Hong, K.; Kirpotin, D. B.; Park, J. W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65 (24), 11631-11638.
14. Zeng, F.; Lee, H.; Allen, C. Epidermal growth factor-conjugated poly(ethylene glycol)-block-poly(δ-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjugate Chem. 2006, 17 (2), 399-409.
15. Kamer, A. R.; Sacks, P. G.; Vladutiu, A.; Liebow, C. EGF mediates multiple signals: Dependence on the conditions. Int. J. Mol. Med. 2004, 13 (1), 143-147.
16. Armstrong, D. K.; Kaufmann, S. H.; Ottaviano, Y. L.; Furuya, Y.; Buckley, J. A.; Isaacs, J. T.; Davidson, N. E. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res. 1994, 54 (20), 5280-5283.
17. Filmus, J.; Pollak, M. N.; Cailleau, R.; Buick, R. N. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Commun. 1985, 128 (2), 898-905.
18. 111In- DTPA-hEGF, chemotherapeutic agents and γ-radiation on EGFR-positive breast cancer cells. Nucl. Med. Biol. 2002, 29 (6), 693-699.
19. Chou, T. C.; Talalay, P. Analysis of combined drug effects - A new look at a very old problem. Trends Pharmacol. Sci. 1983, 4 (11), 450-454.
20. Allen, C.; Maysinger, D.; Eisenberg, A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf., B 1999, 16, 3-27.
21. Liu, J.; Lee, H.; Allen, C. Formulation of drugs in block copolymer micelles: Drug loading and release. Curr. Pharm. Des. 2006, 12 (36), 4685-4701.
22. Liu, J. B.; Xiao, Y. H.; Allen, C. Polymer-drug compatibility: A guide to the development of delivery systems for the anticancer agent, ellipticine. J. Pharm. Sci. 2004, 93 (1), 132-143.
23. Searle, F.; Gac-Breton, S.; Keane, R.; Dimitrijevic, S.; Brocchini, S.; Sausville, E. A.; Duncan, R. N-(2-Hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation. Bioconjugate Chem. 2001, 12 (5), 711-718.
24. Liu, J.; Zeng, F.; Allen, C. Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent. J. Controlled Release 2005, 103 (2), 481-497.
25. Zeng, F.; Allen, C. Synthesis of carboxy-functionalized hetero-bifunctional poly(ethylene glycol) by a thiol-anionic polymerization method. Macromolecules 2006, 39 (19), 6391-6398.
26. Lee, H.; Zeng, F.; Dunne, M.; Allen, C. Methoxy poly(ethylene glycol)-block-poly(δ-valerolactone) copolymer micelles for formulation of hydrophobic drugs. Biomacromolecules 2005, 6 (6), 3119-3128.
27. Soriano, A. F.; Helfrich, B.; Chan, D. C.; Heasley, L. E.; Bunn, P. A.; Chou, T. C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999, 59 (24), 6178-6184.
28. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58 (3), 621-681.
29. Edwards, L. A.; Verreault, M.; Thiessen, B.; Dragowska, W. H.; Hu, Y.; Yeung, J. H.; Dedhar, S.; Bally, M. B. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol. Cancer Ther. 2006, 5 (3), 645-654.
30. Rowinsky, E. K. The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu. Rev. Med. 2004, 55, 433-457.
31. Iwase, H.; Kobayashi, S.; Itoh, Y.; Kuzushima, T.; Yamashita, H.; Iwata, H.; Naito, A.; Yamashita, T.; Itoh, K.; Masaoka, A. Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer. Breast Cancer Res. Treat. 1993, 28 (3), 215-221.
32. Pal, S. K.; Pegram, M. Epidermal growth factor receptor and signal transduction: Potential targets for anti-cancer therapy. Anticancer Drugs 2005, 16 (5), 483-494.
33. Quintela, I.; Corte, M. D.; Allende, M. T.; Vazquez, J.; Rodriguez, J. C.; Bongera, M.; Lamelas, M.; Gonzalez, L. O.; Vega, A.; Garcia-Muniz, J. L.; Astudillo, A.; Vizoso, F. Expression and prognostic value of EGFR in invasive breast cancer. Oncol. Rep. 2005, 14 (6), 1655-1663.
34. Freitas, R. A. Cell membrane. In Nanomedicine; Landes Bioscience: Austin, TX, 1999; Vol. 1, section 8.5.3.2.
35. Carlin, C. R.; Simon, D.; Mattison, J.; Knowles, B. B. Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol. Cell Biol. 1988, 8 (1), 25-34.
36. Mamot, C.; Drummond, D. C.; Greiser, U.; Hong, K.; Kirpotin, D. B.; Marks, J. D.; Park, J. W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003, 63 (12), 3154-3161.
37. Shir, A.; Ogris, M.; Wagner, E.; Levitzki, A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 2006, 3 (1), e6.
38. Normanno, N.; De Luca, A.; Maiello, M. R.; Campiglio, M.; Napolitano, M.; Mancino, M.; Carotenuto, A.; Viglietto, G.; Menard, S. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J. Cell. Physiol. 2006, 207 (2), 420-427.
39. Chen, P.; Cameron, R.; Wang, J.; Vallis, K. A.; Reilly, R. M. Antitumor effects and normal tissue toxicity of In-111-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J. Nucl. Med. 2003, 44 (9), 1469-1478.
40. Rae, J. M.; Lippman, M. E. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res. Treat. 2004, 83 (2), 99-107.
41. Cao, L.; Yao, Y.; Lee, V.; Kiani, C.; Spaner, D.; Lin, Z.; Zhang, Y.; Adams, M. E.; Yang, B. B. Epidermal growth factor induces cell cycle arrest and apoptosis of squamous carcinoma cells through reduction of cell adhesion. J. Cell. Biochem. 2000, 77 (4), 569-583.
42. Gartel, A. L.; Radhakrishnan, S. K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005, 65 (10), 3980-3995.
43. Schaerli, P.; Jaggi, R. EGF-induced programmed cell death of human mammary carcinoma MDA-MB-468 cells is preceded by activation of AP-1. Cell. Mol. Life Sci. 1998, 54 (2), 129-138.
44. Carpenter, G.; Cohen, S. Epidermal growth factor. Annu. Rev. Biochem. 1979, 48, 193-216.
45. Thompson, D. M.; Gill, G. N. The EGF receptor: Structure, regulation and potential role in malignancy. Cancer Surv. 1985, 4 (4), 767-788.
46. Willingham, M. C.; Hanover, J. A.; Dickson, R. B.; Pastan, I. Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc. Natl. Acad. Sci. U.S.A. 1984, 81 (1), 175-179.
47. Sorkin, A. D.; Teslenko, L. V.; Nikolsky, N. N. The endocytosis of epidermal growth factor in A431 cells: A pH of microenvironment and the dynamics of receptor complex dissociation. Exp. Cell Res. 1988, 175 (1), 192-205.
48. Futter, C. E.; Pearse, A.; Hewlett, L. J.; Hopkins, C. R. Multivesicular endosomes containing internalized EGF-EGF receptor complexes mature and then fuse directly with lysosomes. J. Cell Biol. 1996, 132 (6), 1011-1023.
49. Baselga, J.; Norton, L.; Masui, H.; Pandiella, A.; Coplan, K.; Miller, W. H., Jr.; Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 1993, 85 (16), 1327-1333.
50. Yoo, H. S.; Park, T. G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Controlled Release 2004, 96 (2), 273-283.
51. Takahashi, N.; Li, W.; Banerjee, D.; Guan, Y.; Wada-Takahashi, Y.; Brennan, M. F.; Chou, T. C.; Scotto, K. W.; Bertino, J. R. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 2002, 62 (23), 6909-6915.
52. Kuo, P. L.; Hsu, Y. L.; Chang, C. H.; Lin, C. C. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett. 2005, 223 (2), 293-301.
53. Mayer, L. D.; Harasym, T. O.; Tardi, P. G.; Harasym, N. L.; Shew, C. R.; Johnstone, S. A.; Ramsay, E. C.; Bally, M. B.; Janoff, A. S. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 2006, 5 (7), 1854-1863.
54. Tyagi, A. K.; Agarwal, C.; Chan, D. C.; Agarwal, R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol. Rep. 2004, 11 (2), 493-199.
55. Liu, J.; Zeng, F.; Allen, C. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur. J. Pharm. Biopharm. 2007, 65 (3), 309-319.
56. Porschen, R.; Classen, S.; Kahle, Y.; Borchard, F. In situ evaluation of the relationship between epidermal-growth-factor-receptor status and tumor-cell proliferation in colon carcinomas. Int. J. Cancer 1993, 54 (2), 189-193.
57. Torp, S. H.; Helseth, E.; Dalen, A.; Unsgaard, G. Epidermal growth factor receptor expression in human gliomas. Cancer Immunol. Immunother. 1991, 33 (1), 61-64.
58. Buick, R. N.; Filmus, J.; Church, J. Studies of EGF-mediated growth control and signal transduction using the MDA-MB-468 human breast cancer cell line. Prog. Clin. Biol. Res. 1990, 354A, 179-191.
59. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Delivery Rev. 1997, 26 (2-3), 71-90.
60. Chaudhry, M. A. Bystander effect: Biological endpoints and microarray analysis. Mutat. Res. 2006, 597 (1-2), 98-112.
61. Djordjevic, B. Bystander effects: A concept in need of clarification. BioEssays 2000, 22 (3), 286-290.
62. Portsmouth, D.; Hlavaty, J.; Renner, M. Suicide genes for cancer therapy. Mol. Aspects Med. 2007, 28 (1), 4-41.